Published in J Clin Oncol on October 31, 2011
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist (2012) 1.88
Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol (2013) 1.72
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther (2011) 1.57
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol (2014) 1.48
MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer (2012) 1.39
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer (2014) 1.19
MET signaling pathway: a rational target for cancer therapy. J Clin Oncol (2011) 1.17
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer (2014) 1.16
MET is required for the recruitment of anti-tumoural neutrophils. Nature (2015) 1.16
C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS One (2013) 1.16
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch (2014) 1.15
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget (2014) 1.11
Targeting MET Amplification as a New Oncogenic Driver. Cancers (Basel) (2014) 1.11
Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol (2013) 1.10
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist (2012) 1.10
MET amplification as a potential therapeutic target in gastric cancer. Oncotarget (2013) 1.09
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov (2015) 1.07
Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One (2014) 1.03
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs (2013) 1.01
Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget (2015) 1.00
MET in gastric cancer - discarding a 10% cutoff rule. Histopathology (2015) 0.98
Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. Oncoscience (2014) 0.98
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther (2014) 0.97
Novel targeted agents for gastric cancer. J Hematol Oncol (2012) 0.96
HER2 therapies and gastric cancer: a step forward. World J Gastroenterol (2013) 0.96
Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene (2015) 0.94
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood (2014) 0.94
Medical management of gastric cancer: a 2014 update. World J Gastroenterol (2014) 0.94
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One (2014) 0.94
Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol (2014) 0.92
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist (2015) 0.92
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol (2014) 0.92
c-Met as a Target for Personalized Therapy. Transl Oncogenomics (2015) 0.92
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res (2013) 0.92
HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget (2014) 0.92
The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther (2014) 0.91
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol (2012) 0.90
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies. Oncologist (2013) 0.90
Multimodal treatment of esophageal cancer. Langenbecks Arch Surg (2012) 0.88
Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol (2013) 0.87
An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene (2013) 0.87
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist (2013) 0.87
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. Br J Cancer (2015) 0.87
Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget (2015) 0.87
Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol (2015) 0.86
Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol (2016) 0.86
How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist (2014) 0.85
Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf) (2015) 0.85
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. Case Rep Oncol (2014) 0.83
Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene (2014) 0.83
Clinical significance of MET in gastric cancer. World J Gastrointest Oncol (2015) 0.83
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget (2014) 0.83
c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer (2015) 0.83
Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. World J Gastroenterol (2016) 0.83
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch (2012) 0.82
ALK Inhibitors, a Pharmaceutical Perspective. Front Oncol (2012) 0.82
Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol (2016) 0.81
Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol (2014) 0.81
Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann Transl Med (2015) 0.81
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. Br J Cancer (2015) 0.81
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol (2016) 0.81
[Update on Barrett esophagus and Barrett carcinoma]. Pathologe (2012) 0.81
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. Oncologist (2016) 0.81
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget (2016) 0.81
Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics (2013) 0.80
Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors. PLoS One (2015) 0.80
Promise and challenges on the horizon of MET-targeted cancer therapeutics. World J Biol Chem (2015) 0.80
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget (2016) 0.79
Gastric biomarkers: a global review. World J Surg Oncol (2016) 0.79
Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. World J Gastroenterol (2014) 0.79
Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol (2016) 0.79
O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. J Carcinog (2013) 0.79
Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method. Gastric Cancer (2014) 0.79
High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma. Diagn Pathol (2013) 0.79
Gastric cancer: The times they are a-changin'. World J Gastrointest Oncol (2015) 0.79
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma. Oncotarget (2015) 0.79
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer (2014) 0.79
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget (2015) 0.79
MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget (2016) 0.78
Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization. PLoS One (2014) 0.78
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer (2015) 0.78
Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma. Oncotarget (2015) 0.78
Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. J Pathol Transl Med (2015) 0.78
MET targeted therapy for lung cancer: clinical development and future directions. Lung Cancer (Auckl) (2012) 0.78
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. Onco Targets Ther (2015) 0.77
Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. Oncotarget (2016) 0.77
Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs (2016) 0.77
Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res (2015) 0.77
Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget (2015) 0.77
MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer. Gastric Cancer (2015) 0.77
Has MET met its match? Ann Transl Med (2016) 0.76
Biomarker development in MET-targeted therapy. Oncotarget (2016) 0.76
A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report. Onco Targets Ther (2016) 0.75
SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol (2016) 0.75
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer (2016) 0.75
Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther (2007) 7.08
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res (2007) 5.63
Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology (2008) 5.31
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg (2000) 2.85
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun (1992) 2.11
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology (2008) 2.00
Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83
Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest (1998) 1.68
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res (2011) 1.67
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep (2011) 1.66
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res (2010) 1.51
MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.42
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.34
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol (2007) 1.28
Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology (1997) 1.24
Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol (2010) 1.22
Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution. J Am Coll Surg (1999) 1.18
Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. Ann Surg Oncol (2009) 1.12
The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia (2005) 1.12
Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology (1995) 1.10
Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol (2008) 1.02
Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol (2009) 1.00
Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology (1997) 0.97
Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw (2008) 0.97
Combined modality therapy of esophageal cancer. J Natl Compr Canc Netw (2008) 0.97
Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma--emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology (2002) 0.97
Adenocarcinomas on the rise--does it influence survival from oesophageal cancer? Scand J Surg (2009) 0.89
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma. J Natl Compr Canc Netw (2008) 0.83
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell (2008) 11.24
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res (2007) 5.63
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell (2007) 5.19
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74